Predictive Oncology Inc.
US ˙ NasdaqCM ˙ US74039M3097

SecurityPOAI / Predictive Oncology Inc.
InsiderNancy Chung-welch
This page shows the track record and history of CHUNG-WELCH NANCY insider trades in Predictive Oncology Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Nancy Chung-welch in POAI / Predictive Oncology Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

POAI / Predictive Oncology Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Nancy Chung-welch in POAI / Predictive Oncology Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

POAI / Predictive Oncology Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2025-09-11 2025-09-09 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 64,680 83,993
2024-04-12 2024-04-05 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 2,353 21,237
2023-10-04 2023-10-02 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 1,875 16,960
2023-07-05 2023-07-03 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 2,675 15,085
2023-04-05 2023-04-03 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 18,360 248,199
2023-01-04 2023-01-03 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 97,848 229,839
2022-10-05 2022-10-03 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 23,147 131,991
2022-07-05 2022-07-01 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 44,704 108,844
2022-04-05 2022-03-31 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 8,530 64,140
2022-01-06 2022-01-04 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 31,517 55,610
2021-10-05 2021-10-01 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 4,512 24,093
2021-07-06 2021-07-01 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 9,924 19,581
2021-04-02 2021-04-01 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 4,959 9,657
2021-01-05 2020-12-31 4 CHUNG-WELCH NANCY POAI Stock Options (right to buy) A - Award D 0.73 34,135 34,135
2020-10-02 2020-09-30 4 CHUNG-WELCH NANCY POAI Stock Options (right to buy) A - Award D 0.81 6,142 6,142
2020-07-13 3 CHUNG-WELCH NANCY POAI Common Stock D 0
2020-07-13 2020-07-10 4 CHUNG-WELCH NANCY POAI Common Stock A - Award D 4,698 4,698
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)